OBJECTIVE： To systematically evaluate the efficacy and safety of glutathione （GSH） in preventing oxaliplatin-induced peripheral neurotoxicity （OIPN）， and to provide evidence-based reference in the clinic. METHODS： Randomized controlled trials （RCTs） about therapeutic efficacy of GSH vs. placebo/no any measures （called placbo group） or other drug in preventing OIPN were retrieved from PubMed， EMBase， Cochrane library， CJFD， Wanfang database and VIP. Meta-analysis was performed with Rev Man 5.3 statistical software after data extraction and quality evaluation with Jadad scale.  RESULTS： 18 RCTs were included， involving 1 200 patients. The results of Meta-analysis showed that： total incidence of oxaliplatin-induced chronic peripheral neurotoxicity （OICPN）[RR＝0.71，95％CI（0.59，0.87），P＜0.001] and the incidence of severe OICPN [RR＝0.50，95％CI（0.42，0.60），P＜0.001] in GSH group were significantly lower than placebo group， with statistical significance； there was statistical significance in the incidence of oxaliplatin-induced acute peripheral neurotoxicity （OIAPN）[RR＝0.89，95％CI（0.72，1.09），P＝0.25]. The incidence of severe OICPN in GSH group was significantly higher than mecobalamine group， with statistical significance [RR＝2.06，95％CI（1.07，3.99），P＝0.03]. There was no statistical significance in the incidence of OICPN[RR＝1.38，95％CI（0.83，2.31），P＝0.21] and severe OICPN [RR＝1.91，95％CI（0.85， 4.30），P＝0.12] between GSH group and Ca+Mg mixture group. CONCLUSIONS： GSH can effectively prevent the occurrence of OICPN， however， its therapeutic efficacy is equivalent to Ca+Mg mixture and inferior to mecobalamine in preventing severe OICPN.